Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms

Trial Profile

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs APR 246 (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Dec 2018 According to an Aprea media release, results (n=20) from this trial were presented at the 2018 American Society of Hematology (ASH) Annual Meeting (San Diego).
    • 02 Dec 2018 Results (n=20) presented in an Aprea media release.
    • 30 Nov 2018 According to an Aprea Therapeutics media release, the company is nearing completion of this trial.The phase II part of the study is ongoing, with updated data to be presented at the 2018 American Society of Hematology (ASH) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top